Alentis TherapeuticsSwiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.
ADVERTISEMENT
Swiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.